[go: up one dir, main page]

MW390A1 - Antiviral or antibacterial compound and method of use - Google Patents

Antiviral or antibacterial compound and method of use

Info

Publication number
MW390A1
MW390A1 MW3/90A MW390A MW390A1 MW 390 A1 MW390 A1 MW 390A1 MW 3/90 A MW3/90 A MW 3/90A MW 390 A MW390 A MW 390A MW 390 A1 MW390 A1 MW 390A1
Authority
MW
MALAWI
Prior art keywords
antiviral
composition
disclosed
antibacterial compound
forms
Prior art date
Application number
MW3/90A
Original Assignee
Nika Health Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Ltd filed Critical Nika Health Products Ltd
Publication of MW390A1 publication Critical patent/MW390A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

A composition having antiviral and antibacterial effects is disclosed which comprises the dimeric forms of enzymes selected from lysozyme and ribonuclease and a pharmaceutically acceptable carrier. These dimeric forms are more effective in treating a variety of human and animal diseases because they are much less cytotoxic than the monomeric forms of the enzyme. A method for the use of these compositions is also disclosed which comprises applying an effective amount of the composition to the infected area.
MW3/90A 1988-05-26 1990-01-22 Antiviral or antibacterial compound and method of use MW390A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17858888A 1988-05-26 1988-05-26
PCT/US1988/001785 WO1989011294A1 (en) 1988-05-26 1988-05-26 Antiviral or antibacterial compound and method of use
OA59731A OA09785A (en) 1988-05-26 1990-01-26 Antiviral or antibacterial compound and method of use

Publications (1)

Publication Number Publication Date
MW390A1 true MW390A1 (en) 1990-11-14

Family

ID=33162813

Family Applications (1)

Application Number Title Priority Date Filing Date
MW3/90A MW390A1 (en) 1988-05-26 1990-01-22 Antiviral or antibacterial compound and method of use

Country Status (23)

Country Link
US (3) US5200182A (en)
EP (1) EP0380484B1 (en)
JP (1) JPH0649659B2 (en)
AT (1) ATE93143T1 (en)
AU (1) AU624331B2 (en)
BG (1) BG60544B1 (en)
CA (1) CA1335425C (en)
CS (1) CS277030B6 (en)
DK (1) DK173078B1 (en)
ES (1) ES2011577A6 (en)
FI (1) FI900412A7 (en)
HK (1) HK42394A (en)
HU (1) HU204710B (en)
IL (1) IL90092A (en)
LV (1) LV10054B (en)
MA (1) MA21560A1 (en)
MW (1) MW390A1 (en)
OA (1) OA09785A (en)
PH (1) PH26284A (en)
RU (1) RU2092183C1 (en)
WO (1) WO1989011294A1 (en)
YU (1) YU109289A (en)
ZA (1) ZA893382B (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200182A (en) * 1988-05-26 1993-04-06 Nika Health Products, Ltd. Antiviral or antibacterial composition and method of use
AU645252B2 (en) * 1990-01-08 1994-01-13 Nika Health Products Ltd. Method of producing ribonuclease dimers
US5989880A (en) * 1990-01-08 1999-11-23 Nika Health Products Ltd. Method of preparing lysozyme dimers
PL173978B1 (en) * 1992-07-13 1998-05-29 Nika Health Products Ltd Method of obtaining a preparation capable to retard the synthesis of endogenous cytotoxic cytokinins
CH682541A5 (en) * 1992-06-23 1993-10-15 Urs Viktor Dr Wirth Biochemical Inactivation of RNA viruses.
US6183742B1 (en) 1992-07-13 2001-02-06 Nika Health Products, Limited Applications of lysozyme dimer
DZ1964A1 (en) * 1995-01-13 2002-10-15 Nika Health Products Ltd New applications of a lysozyme dimer.
GB2304048A (en) * 1995-08-12 1997-03-12 John William Carson Medicament containing saliva extract
US6123937A (en) * 1997-03-14 2000-09-26 Nika Health Products, Limited Applications of lysozyme dimer
RU2157206C1 (en) * 1999-03-10 2000-10-10 Оренбургская государственная медицинская академия Bactericidal otogel
RU2172179C2 (en) * 1999-06-24 2001-08-20 Сельков Сергей Алексеевич Globuli "biosan" for treatment of patients with colpitis of different genesis and method of treatment of patients with colpitis of different genesis
RU2191576C2 (en) * 1999-07-27 2002-10-27 Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии Method for treating subclinical form of female genital herpesvirus infection
RU2200550C2 (en) * 1999-10-29 2003-03-20 Научно-исследовательская лаборатория иммунохимиотерапии лепры и иммунотропных средств с клиникой и опытно-экспериментальным производством Novel medicinal forms of dimocifon in leprosy therapy, itching and allergodermatosis, during's dermatitis herpetiformis
RU2163119C1 (en) * 2000-04-26 2001-02-20 Свистов Виталий Владимирович Antiseptic agent
RU2180593C1 (en) * 2000-11-08 2002-03-20 Айламазян Эдуард Карпович Pharmaceutical composition for treatment and prophylaxis of genital herpes, chronic papilloma of viral infection and prophylaxis of uterine cervix cancer (variants)
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US6716813B2 (en) * 2000-11-28 2004-04-06 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
RU2177781C1 (en) * 2000-12-06 2002-01-10 Научный Центр Здоровья детей РАМН Vitamin complex-containing rectal suppositories
JP2002187853A (en) * 2000-12-21 2002-07-05 Shinei Ferumentekku:Kk Disinfectiong agent for nipple of animal, and method for improving fungal environment
RU2195927C1 (en) * 2001-07-13 2003-01-10 ООО "Тенториум" Candella-2 abies-candle
DE10210285A1 (en) * 2002-03-08 2003-11-13 Medigene Ag Reversible toxin and its use
WO2005115477A2 (en) * 2004-04-13 2005-12-08 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
US7348301B2 (en) * 2006-02-16 2008-03-25 Buckman Laboratories International, Inc. Lysozyme-based method and composition to control the growth of microorganisms in aqueous systems
WO2007149594A2 (en) * 2006-06-23 2007-12-27 Quintessence Biosciences, Inc. Modified ribonucleases
US8298801B2 (en) 2006-07-17 2012-10-30 Quintessence Biosciences, Inc. Methods and compositions for the treatment of cancer
EP2134354A4 (en) * 2007-03-02 2012-03-21 Saint Simeon Lda Composition and method for treating papilloma virus and equine sarcoids
WO2009036000A2 (en) * 2007-09-11 2009-03-19 University Of Maryland, Baltimore Methods of treating a microbial infection by modulating rnase-l expression and/or activity
US8697062B2 (en) * 2007-10-08 2014-04-15 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapeutics
CN102227443B (en) 2008-10-01 2014-05-14 昆特森斯生物科学公司 Therapeutic ribonucleases
US20100215707A1 (en) * 2009-02-25 2010-08-26 Mcdonald Thomas Activated creatinine and precursors thereof as antibacterial agents, compositions and products containing such agents and uses thereof
NZ600269A (en) 2009-05-20 2014-02-28 Dec Int Nz Ltd Delivery device for treatment of mastitis
PL2457576T3 (en) 2010-11-29 2021-04-06 Eurochit Danuta Kruszewska Lactobacillus reuteri strain for use in the medical and veterinary prophylaxis and treatment of metabolic syndrome or infections
RU2548803C2 (en) * 2011-11-28 2015-04-20 Общество с ограниченной ответственностью " Фарматренд" PHARMACEUTICAL COMPOSITION FOR TREATING EYE INFECTIONS P. Aeruginosa CONTAINING RECOMBINANT LYSOZYME
RU2509801C2 (en) * 2012-03-22 2014-03-20 Борис Михайлович Куриненко METHOD OF USING Bacillus intermedius RIBONUCLEASE
EP2674162A1 (en) 2012-05-29 2013-12-18 Danuta Kruszewska Nanoproduct comprising lactobacillus reuteri dan080 useful in prophylaxis and medicine, both human and veterinary and medical use of the same
JP2015520773A (en) 2012-05-29 2015-07-23 ダヌタ・クルセフスカＤａｎｕｔａＫＲＵＳＺＥＷＳＫＡ Nano products containing Lactobacillus reuteri DAN80 useful for prevention and medicine in humans and animals and their pharmaceutical use
RU2504397C1 (en) * 2012-10-25 2014-01-20 Леонид Леонидович Клопотенко Pharmaceutical composition containing enzyme ribonuclease and glycyrrhizic acid or salts thereof: ammonium or dipotassium or trisodium glycyrrhizinate
WO2014152678A1 (en) 2013-03-15 2014-09-25 University Of Massachusetts Compositions and methods for delivering agents to the central nervous system
US9573980B2 (en) 2013-03-15 2017-02-21 Spogen Biotech Inc. Fusion proteins and methods for stimulating plant growth, protecting plants from pathogens, and immobilizing Bacillus spores on plant roots
WO2015125961A1 (en) 2014-02-21 2015-08-27 国立大学法人東京海洋大学 Norovirus inactivator and method for producing same, method for inactivating norovirus, method for producing lysozyme component for norovirus inactivation use, prophylactic or therapeutic agent for norovirus infection, and external preparation for skin for norovirus inactivation purposes
EP3175713A4 (en) * 2014-07-31 2018-04-18 Kewpie Corporation Water-containing fluid composition, method for producing same, processed lysozyme and/or salt thereof, and method for producing same
IL315468A (en) 2014-09-17 2024-11-01 Spogen Biotech Inc Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria
LV15071B (en) * 2015-07-14 2016-02-20 Rīgas Stradiņa Universitāte Composition for treating subclinical mastitis in cows
RU2634264C1 (en) * 2016-09-19 2017-10-24 Александр Ливиевич Ураков Cream-milk for zoster treatment
CN113861760B (en) 2016-12-28 2023-05-05 Dic株式会社 Dispersion body
EP3684168A4 (en) 2017-09-20 2021-10-27 Spogen Biotech Inc. FUSION PROTEINS, RECOMBINANT BACTERIA AND EXIN FRAGMENTS FOR PLANT HEALTH
WO2021021765A1 (en) * 2019-07-26 2021-02-04 Evolve Biosystems, Inc. Nutritive compositions with bioactive proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1268M (en) * 1961-06-29 1962-04-24 Puiseux Antimitotic and antiviral drug.
FR4020M (en) * 1965-01-29 1966-03-21
DE1517751C3 (en) * 1965-07-08 1975-02-27 Eisai Co., Ltd., Tokio Method for preventing the formation of flaky lysozyme and / or lysozyme salt precipitates in aqueous solutions containing lysozyme and / or lysozyme salts
DE1545644A1 (en) * 1965-12-06 1969-08-07 Boehringer Sohn Ingelheim Process for the preparation of new quaternary scopolammonium salts
GB1110504A (en) * 1966-03-18 1968-04-18 Prodotti Antibiotici Spa Pharmaceutical compositions
US4221794A (en) * 1979-06-21 1980-09-09 Newport Pharmaceuticals International, Inc. Method of imparting immunomodulating and antiviral activity
US4510144A (en) * 1981-08-26 1985-04-09 Newport Pharmaceuticals International Methods of imparting immunomodulating activity with dihydrothiazolo purine derivatives
EP0187705A3 (en) * 1985-01-08 1988-05-11 Norwich Eaton Pharmaceuticals, Inc. Imidazo(4,5-f)quinolines useful as immunomodulating agents
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US5200182A (en) * 1988-05-26 1993-04-06 Nika Health Products, Ltd. Antiviral or antibacterial composition and method of use

Also Published As

Publication number Publication date
AU624331B2 (en) 1992-06-11
BG91270A (en) 1993-12-24
MA21560A1 (en) 1989-12-31
CS318089A3 (en) 1992-05-13
YU109289A (en) 1991-08-31
EP0380484A1 (en) 1990-08-08
DK16890A (en) 1990-01-22
HUT54060A (en) 1991-01-28
ZA893382B (en) 1991-01-30
US5200182A (en) 1993-04-06
CS277030B6 (en) 1992-11-18
EP0380484B1 (en) 1993-08-18
LV10054A (en) 1994-05-10
WO1989011294A1 (en) 1989-11-30
CA1335425C (en) 1995-05-02
PH26284A (en) 1992-04-10
DK173078B1 (en) 1999-12-20
US5466449A (en) 1995-11-14
JPH0649659B2 (en) 1994-06-29
HU204710B (en) 1992-02-28
JPH03504121A (en) 1991-09-12
RU2092183C1 (en) 1997-10-10
IL90092A (en) 1995-03-30
HK42394A (en) 1994-05-13
ES2011577A6 (en) 1990-01-16
AU1940888A (en) 1989-12-12
BG60544B1 (en) 1995-08-28
ATE93143T1 (en) 1993-09-15
FI900412A0 (en) 1990-01-25
LV10054B (en) 1995-02-20
US6099835A (en) 2000-08-08
FI900412A7 (en) 1990-01-25
OA09785A (en) 1994-04-15
HU883981D0 (en) 1990-12-28
DK16890D0 (en) 1990-01-22

Similar Documents

Publication Publication Date Title
OA09785A (en) Antiviral or antibacterial compound and method of use
UA39158C2 (en) derivatives of N4-oxycarbonyl- 5'-deoxy-5-fluorocytidine and pharmaceutical preparation based thereon
MX9702932A (en) L-ribofuranosyl nucleosides.
AU7211787A (en) Intraocular dosage compositions and method of use
MY110734A (en) Improvements in or relating to dioic acids.
AU5287090A (en) Method and composition for treatment of periodontal disease
AU693833B2 (en) Products containing G-CSF and TNF binding protein
ZA898605B (en) Compositions for topical treatment of skin diseases
JO1610B1 (en) Antiviral tetrahydroimidazo (1,4) benzodiazepin -2- thiones
JO1589B1 (en) Antiviral tetrahydroimidazo(1,4)benzodiazepin-2-ones
ZA929947B (en) Method of imparting antimicrobial activity to an opthalmic composition.
EP0813409A4 (en) Treatment of cytokine growth factor caused disorders
AU2840889A (en) Method of treating haematologic diseases and pharmaceutical compositions to be used therefor
HUT50844A (en) Process for producing new 2'-halogen methylidene, 2'-ethenylidene and 2'-ethinyladenosine derivatives and pharmaceutical compositions comprising same as active ingredient
GEP20012511B (en) Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
MY106984A (en) Antiviral or antibacterial composition and method of use.
AU591017B2 (en) Human monoclonal antibody and drug for prophylaxis and treatment of infectious diseases comprising same as effective ingredient
GEP19971029B (en) Antiviral or antibacterial compound and method of use thereof
GR1001006B (en) Method for preparating and using antimicrobiac or antibacterial compositions
CA2097878A1 (en) Therapeutic agent for neutropenia
EP0491873A4 (en) Therapeutic compositions; methods for treatment of hiv infections
AU2314488A (en) Anthelmintic acylhydrazones, method of use and compositions
MX9307639A (en) METHOD FOR TREATING VIRAL INFECTIONS WITH CONJUNCTIVE THERAPY WITH COMPOUNDS SIMILAR TO ACICLOVIR AND AN ANALOGUE OF 2'-VIRIL SUBSTITUTED NUCLEOSIDE.
MY104932A (en) Immunomodulatory azaspiranes
HRP930588B1 (en) Process for the preparation of therapeutic transdermal system having physostigmine as an active ingredient